Drug Profile
Research programme: vancomycin analogues - Incara/Merck & Co
Latest Information Update: 23 Jul 2001
Price :
$50
*
At a glance
- Originator Incara Pharmaceuticals Corporation; Merck & Co
- Class
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 23 Jul 2001 Discontinued-Preclinical for Bacterial infections in USA (Unknown route)
- 13 Aug 1999 Preclinical development for Bacterial infections in USA (Unknown route)